根治性放疗后生化复发前列腺癌的自然史与风险分层
本研究基于美国退伍军人健康系统7126例放疗后生化复发(BCR)前列腺癌患者,验证欧洲共识指南的高危BCR分层(Gleason≥8或放疗后18个月内复发)。38.5%为高危BCR,其10年转移发生率56.2% vs 42.0%,前列腺癌特异性生存69.5% vs 81.6%,全因死亡67.8% vs 65.0%。该双要素分层工具可识别转移或死亡高风险患者。
要点
- 放疗后BCR患者10年转移率35.5%,前列腺癌死亡率17.4%。
- 高危BCR(Gleason≥8或18个月内复发)占38.5%,转移风险显著更高。
- 双要素分层工具可辅助治疗决策和临床试验人群筛选。
核心结论
- 基于Gleason评分≥8或放疗后18个月内BCR的双要素分层工具,是首个验证的放疗后BCR风险分层工具。
- 多数放疗后BCR患者不发生转移或致死性前列腺癌,分层对治疗决策和临床试验人群细化至关重要。
研究设计与样本
- 回顾性、多中心、全国性队列研究,使用美国退伍军人健康系统数据。
- 纳入7126例根治性放疗后出现BCR的前列腺癌患者。
- 高危BCR定义为Gleason评分≥8或放疗后18个月内出现BCR。
主要发现
- 全部BCR患者10年转移发生率为35.5%,前列腺癌死亡率为17.4%。
- 38.5%的患者为高危BCR。
- 高危BCR患者10年转移发生率56.2% vs 42.0%(aHR=1.83,95%CI:1.69-1.98)。
- 高危BCR患者前列腺癌特异性生存69.5% vs 81.6%(aHR=1.82,95%CI:1.63-2.03,P<.001)。
- 高危BCR患者全因死亡67.8% vs 65.0%(aHR=1.18,95%CI:1.11-1.26,P<.001)。
关键数值与推荐
- 高危BCR定义:Gleason评分≥8或放疗后18个月内出现BCR(依据欧洲共识指南)。
- 高危BCR与10年转移风险升高相关(56.2% vs 42.0%,aHR=1.83,95%CI:1.69-1.98)。
- 高危BCR与更差的前列腺癌特异性生存相关(69.5% vs 81.6%,aHR=1.82,95%CI:1.63-2.03,P<.001)。
临床怎么用
- 利用现有临床数据(Gleason评分和BCR时间)对放疗后BCR患者进行简易风险分层。
- 高危BCR患者可考虑更密切监测或强化治疗策略。
- 该分层工具可用于临床试验筛选高风险人群。
局限性
- 回顾性研究设计。
- 数据来源于美国退伍军人健康系统,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Among patients with biochemical recurrent (BCR) prostate cancer following radiation therapy, there is no validated method for identifying those at the highest risk for metastases or death from prostate cancer. We characterized the natural history of BCR after radiation therapy and validated the proposed European consensus guidelines for stratification. METHODS AND MATERIALS: This retrospective, multicenter, nationwide cohort study used data from patients having postradiation BCR treated in the United States Veterans Administration Health System. High-risk BCR was defined as either Gleason score ≥8 or BCR occurring within 18 months of radiation therapy, per guidelines. RESULTS: Among 7126 patients who experienced BCR, 35.5% of patients developed metastatic disease and 17.4% died of prostate cancer at 10 years. 38.5% of patients had a high-risk BCR. High-risk BCR resulted in higher 10-year incidence of metastatic disease (56.2% vs 42.0%, adjusted hazard ratio [aHR] = 1.83, 95% CI: 1.69-1.98) and worse prostate cancer-specific survival (69.5% vs 81.6%, aHR = 1.82, 95% CI: 1.63-2.03, P < .001) and all-cause death (67.8% vs 65.0%, aHR = 1.18, 95% CI: 1.11-1.26, P < .001). CONCLUSIONS: A simple, 2-element risk stratification tool using existing clinical data is the first validated tool for identifying patients at risk of metastases or prostate cancer-specific mortality following postradiation BCR. Most patients experiencing BCR in this context do not develop metastases or lethal prostate cancer, making such stratification essential for treatment decision-making and refinement of patient populations for clinical trials.
引用
- Riviere P, Morgan KM, Nelson T, et al. Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy. Adv Radiat Oncol. 2025. PMID: 41583333. doi:10.1016/j.adro.2025.101936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。